Literature DB >> 27648580

Tackling breast cancer chemoresistance with nano-formulated siRNA.

S K Jones1, O M Merkel1,2,3.   

Abstract

Breast cancer is the leading cancer diagnosed in women and the second leading cause of cancer-related deaths in women. Current limitations to standard chemotherapy in the clinic are extensively researched, including problems arising from repeated treatments with the same drugs. The phenomenon that cancer cells become resistant toward certain chemo drugs is called chemotherapy resistance. In this review, we are focusing on nanoformulation of siRNA for the fight against breast cancer chemoresistance.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27648580      PMCID： PMC5540231          DOI： 10.1038/gt.2016.67

Source DB:  PubMed          Journal:  Gene Ther        ISSN： 0969-7128            Impact factor:   5.250


  83 in total

Review 1.  Delivery of siRNA therapeutics: barriers and carriers.

Authors:  Jie Wang; Ze Lu; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2010-06-11       Impact factor: 4.009

2.  Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.

Authors:  S Seitz; F G Rick; A V Schally; A Treszl; F Hohla; L Szalontay; M Zarandi; O Ortmann; J B Engel; S Buchholz
Journal:  Oncol Rep       Date:  2013-04-29       Impact factor: 3.906

Review 3.  Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells.

Authors:  Ying Huang; Wolfgang Sadée
Journal:  Cancer Lett       Date:  2005-10-05       Impact factor: 8.679

4.  A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA.

Authors:  Kazuya Nakamura; Amr S Abu Lila; Mariko Matsunaga; Yusuke Doi; Tatsuhiro Ishida; Hiroshi Kiwada
Journal:  Mol Ther       Date:  2011-08-30       Impact factor: 11.454

Review 5.  Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer.

Authors:  Meysam Abbasi; Afsaneh Lavasanifar; Hasan Uludag
Journal:  Med Res Rev       Date:  2011-04-26       Impact factor: 12.944

6.  Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy.

Authors:  Cuifang Zheng; Mingbin Zheng; Ping Gong; Jizhe Deng; Huqiang Yi; Pengfei Zhang; Yijuan Zhang; Peng Liu; Yifan Ma; Lintao Cai
Journal:  Biomaterials       Date:  2013-01-31       Impact factor: 12.479

7.  Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells.

Authors:  Ugur Akar; Arturo Chaves-Reyez; Magaly Barria; Ana Tari; Angela Sanguino; Yasuko Kondo; Seiji Kondo; Banu Arun; Gabriel Lopez-Berestein; Bulent Ozpolat
Journal:  Autophagy       Date:  2008-04-10       Impact factor: 16.016

Review 8.  Targeting multidrug resistance in cancer.

Authors:  Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

9.  The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance.

Authors:  Yogesh B Patil; Suresh K Swaminathan; Tanmoy Sadhukha; Linan Ma; Jayanth Panyam
Journal:  Biomaterials       Date:  2009-10-01       Impact factor: 12.479

10.  Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi).

Authors:  Christiane Nieth; Axel Priebsch; Alexandra Stege; Hermann Lage
Journal:  FEBS Lett       Date:  2003-06-19       Impact factor: 4.124
View more
  4 in total

Review 1.  Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives.

Authors:  Wolfgang Poller; Stefanie Dimmeler; Stephane Heymans; Tanja Zeller; Jan Haas; Mahir Karakas; David-Manuel Leistner; Philipp Jakob; Shinichi Nakagawa; Stefan Blankenberg; Stefan Engelhardt; Thomas Thum; Christian Weber; Benjamin Meder; Roger Hajjar; Ulf Landmesser
Journal:  Eur Heart J       Date:  2018-08-01       Impact factor: 29.983

2.  Correlating quantitative tumor accumulation and gene knockdown using SPECT/CT and bioluminescence imaging within an orthotopic ovarian cancer model.

Authors:  Steven K Jones; Kirk Douglas; Anthony F Shields; Olivia M Merkel
Journal:  Biomaterials       Date:  2018-06-13       Impact factor: 12.479

3.  NT21MP negatively regulates paclitaxel-resistant cells by targeting miR‑155‑3p and miR‑155-5p via the CXCR4 pathway in breast cancer.

Authors:  Yueyue Wang; Lei Yan; Lingyu Zhang; Henan Xu; Tiantian Chen; Yu Li; Haifeng Wang; Sulian Chen; Wenrui Wang; Changjie Chen; Qingling Yang
Journal:  Int J Oncol       Date:  2018-07-09       Impact factor: 5.650

4.  In-Vitro Application of Magnetic Hybrid Niosomes: Targeted siRNA-Delivery for Enhanced Breast Cancer Therapy.

Authors:  Viktor Maurer; Selin Altin; Didem Ag Seleci; Ajmal Zarinwall; Bilal Temel; Peter M Vogt; Sarah Strauß; Frank Stahl; Thomas Scheper; Vesna Bucan; Georg Garnweitner
Journal:  Pharmaceutics       Date:  2021-03-16       Impact factor: 6.321
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.